Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. engages in developing protein-based fibers using recombinant DNA technology for commercial applications in the technical textile and specialty fiber industries in the United States. The company's products are used in military and police applications for ballistic protection; industrial applications, including critical cables and abrasion/impact resistant components; safety equipment; and composite materials for the aero-space industry. Its products are also used in various markets, such as medical textiles, geotextiles, defense and military textiles, safe and protective clothing, filtration textiles, composites with textile structure, and functional and sportive textiles, as well as textiles used in buildings and transportation. The company was incorporated in 2006 and is headquartered in Ann Arbor, Michigan.

Kraig Biocraft Laboratories, Inc. trades as KBLB on OTC. The company is classified in Basic Materials / Chemicals - Specialty and reports in USD.

The current profile places the business in Chemicals - Specialty. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $0 of revenue and -$3.62M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Kraig Biocraft Laboratories, Inc. can be compared against peers such as AirBoss of America Corp., Bear Creek Mining Corporation, Blackstone Minerals Limited, Galan Lithium Limited, Graphene Manufacturing Group Ltd, Geopacific Resources Limited.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $133.57M, beta of 1.48, and return on equity of +45.3%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

KBLB currently shows total debt of $1.66M and beta of 1.48. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: 424B3 (2026-05-22 00:00:00), 424B3 (2026-05-22 00:00:00), 424B3 (2026-05-22 00:00:00), 10-Q (2026-05-14 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.kraiglabs.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.